California Public Employees Retirement System Has $165.30 Million Holdings in Becton, Dickinson and Company $BDX

California Public Employees Retirement System cut its position in Becton, Dickinson and Company (NYSE:BDX) by 17.1% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 883,172 shares of the medical instruments supplier’s stock after selling 181,906 shares during the quarter. California Public Employees Retirement System owned about 0.31% of Becton, Dickinson and Company worth $165,303,000 as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in BDX. Activest Wealth Management increased its stake in shares of Becton, Dickinson and Company by 285.3% during the 3rd quarter. Activest Wealth Management now owns 131 shares of the medical instruments supplier’s stock worth $25,000 after purchasing an additional 97 shares during the last quarter. Imprint Wealth LLC acquired a new stake in Becton, Dickinson and Company in the 3rd quarter valued at about $25,000. SOA Wealth Advisors LLC. grew its holdings in Becton, Dickinson and Company by 256.8% during the third quarter. SOA Wealth Advisors LLC. now owns 132 shares of the medical instruments supplier’s stock worth $25,000 after purchasing an additional 95 shares during the period. Bell Investment Advisors Inc grew its holdings in Becton, Dickinson and Company by 474.1% during the second quarter. Bell Investment Advisors Inc now owns 155 shares of the medical instruments supplier’s stock worth $27,000 after purchasing an additional 128 shares during the period. Finally, Accredited Wealth Management LLC increased its position in Becton, Dickinson and Company by 77.8% during the third quarter. Accredited Wealth Management LLC now owns 160 shares of the medical instruments supplier’s stock worth $30,000 after buying an additional 70 shares during the last quarter. 86.97% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research firms have recently issued reports on BDX. Piper Sandler reaffirmed a “neutral” rating and issued a $170.00 price objective (down from $205.00) on shares of Becton, Dickinson and Company in a research report on Tuesday, February 10th. Wells Fargo & Company dropped their price target on Becton, Dickinson and Company from $184.00 to $157.00 and set an “equal weight” rating on the stock in a research note on Tuesday, February 10th. Jefferies Financial Group cut their price target on Becton, Dickinson and Company from $220.00 to $190.00 and set a “buy” rating for the company in a report on Tuesday, February 10th. Citigroup decreased their price objective on shares of Becton, Dickinson and Company from $233.00 to $232.00 and set a “buy” rating on the stock in a report on Tuesday, February 10th. Finally, TD Cowen increased their price objective on shares of Becton, Dickinson and Company from $183.00 to $189.00 and gave the company a “hold” rating in a research report on Wednesday, February 11th. Five investment analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $195.46.

Becton, Dickinson and Company Stock Performance

Shares of NYSE BDX opened at $159.32 on Monday. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.05 and a quick ratio of 0.58. The firm has a market cap of $45.36 billion, a price-to-earnings ratio of 25.99, a P/E/G ratio of 11.55 and a beta of 0.24. The stock’s fifty day moving average price is $190.01 and its two-hundred day moving average price is $189.97. Becton, Dickinson and Company has a one year low of $127.59 and a one year high of $187.35.

Becton, Dickinson and Company (NYSE:BDX) last posted its earnings results on Monday, February 9th. The medical instruments supplier reported $2.91 earnings per share for the quarter, topping analysts’ consensus estimates of $2.81 by $0.10. The company had revenue of $5.25 billion during the quarter, compared to the consensus estimate of $5.15 billion. Becton, Dickinson and Company had a return on equity of 15.76% and a net margin of 8.01%.The company’s revenue was up 1.6% on a year-over-year basis. During the same quarter last year, the firm earned $3.43 earnings per share. Becton, Dickinson and Company has set its FY 2026 guidance at 12.350-12.650 EPS. On average, equities analysts forecast that Becton, Dickinson and Company will post 14.43 EPS for the current year.

Becton, Dickinson and Company Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, March 31st. Investors of record on Tuesday, March 10th will be given a dividend of $1.05 per share. This represents a $4.20 dividend on an annualized basis and a yield of 2.6%. The ex-dividend date of this dividend is Tuesday, March 10th. Becton, Dickinson and Company’s dividend payout ratio (DPR) is currently 68.52%.

Becton, Dickinson and Company declared that its Board of Directors has authorized a stock buyback plan on Tuesday, January 27th that authorizes the company to repurchase $10.00 million in shares. This repurchase authorization authorizes the medical instruments supplier to repurchase up to 0% of its shares through open market purchases. Shares repurchase plans are generally a sign that the company’s board of directors believes its shares are undervalued.

Insider Transactions at Becton, Dickinson and Company

In other Becton, Dickinson and Company news, EVP Michael David Garrison sold 1,610 shares of the business’s stock in a transaction dated Thursday, January 15th. The shares were sold at an average price of $207.46, for a total value of $334,010.60. Following the completion of the sale, the executive vice president owned 12,095 shares of the company’s stock, valued at $2,509,228.70. The trade was a 11.75% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Bertram L. Scott sold 953 shares of the stock in a transaction that occurred on Wednesday, February 18th. The stock was sold at an average price of $182.61, for a total transaction of $174,027.33. Following the transaction, the director owned 36,763 shares in the company, valued at approximately $6,713,291.43. The trade was a 2.53% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 3,416 shares of company stock valued at $674,693 in the last three months. Insiders own 0.40% of the company’s stock.

About Becton, Dickinson and Company

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.